Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for April 2012
April 2, 2012
- Ablynx Receives Milestone Payment As Collaborator Receives IND Approval for A Nanobody in Oncology
- Actelion Provides Update on CRTH2 Program
- Collaboration With Zydus Cadila Expires ? Karo Bio Continues to Develop Safer Glucocorticoids
- GlaxoSmithKline to Increase Its Ownership in Theravance
- Astellas and Vical Advance Toward Phase 3 Trial of Transvax CMV Vaccine Triggering $10 Million Milestone Payment to Vical
- Ranbaxy Receives Approval to Market Ran-Rosuvastatin in Canada
- Forest Laboratories, Inc. Announces Buyout of Bystolic Royalties from Janssen Pharmaceutica NV
- Express Scripts and Medco Health Solutions Complete Merger; Will Address National Mandate for More Affordable, Higher Quality Healthcare
- FTC Closes Eight-Month Investigation of Express Scripts, Inc.'s Proposed Acquisition of Pharmacy Benefits Manager Medco Health Solutions, Inc.
- VaxInnate Names Wayne Pisano as its New CEO
- Illumina's Board Unanimously Rejects Roche's Revised Unsolicited Offer
- Amgen and AstraZeneca Announce Collaboration to Jointly Develop and Commercialize Clinical-Stage Inflammation Portfolio
- Teva Announces Launch of Generic Avapro and Generic Avalide in the United States
April 3, 2012
- Astellas CSR Website Renewed
- Roche disappointed by Illumina, Inc.'s Board of Directors' rejection
- inVentiv Health Completes Acquisition of Kforce Clinical Research
- Watson Confirms Favorable District Court Ruling in Generic Sanctura XR Patent Suit
- Illumina's Board of Directors Sends Third Letter to Stockholders
April 4, 2012
- FDA - Altuzan (bevacizumab): Counterfeit Product - Contains no Active Ingredient
- Roche Sends Second Letter to Illumina Shareholders
- Icahn Issues Open Letter to the Board of Directors of Amylin Pharmaceuticals
- Randy Jackson Partners with Merck to Urge People with Type 2 Diabetes to Take Their Diabetes to Heart
- UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis
- Despite the Current Industry Environment, Cegedim Strategic Data Reports A Decline of Only 1.8% in Worldwide Pharmaceutical Sales Force Levels in 2011
- Breakthrough Treatments, Fewer Doctor Office Visits, Reduced Use of Medicines Impact U.S. Healthcare in 2011, According to IMS Study
- AstraZeneca Investors Encouraged By Partnership With US Group Amgen, but FTSE Slips Back
April 5, 2012
- Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012
- FDA Decides Teva is Sole First-to-File on Provigil
- Merck Statement On Nasonex (mometasone furoate monohydrate) Patent Trial in the U.S. District Court for the District of New Jersey
- Gov. Christie Meets With Teva in Israel
- Biogen Reaches All-Time Highs and Gets Upgrade
April 6, 2012
April 9, 2012
- Optimer Pharmaceuticals Announces Personnel Changes
- Lilly Says FDA Approves Brain Imaging Agent
- Johnson & Johnson Announces Resignation of Sheri S. McCoy
- Abbott Receives Approval for Next-Generation Xience Prime Drug Eluting Stent in Japan
- Illumina's Board of Directors Sends Fourth Letter to Stockholders
- Icahn Files Lawsuit Against Amylin Pharmaceuticals
- Affymax Receives a $50 Million Milestone Payment for U.S. Approval of OMONTYS (peginesatide) Injection
April 10, 2012
- EpiCept's AmiKet Receives Fast Track Designation from FDA
- ViroPharma Provides Update on Status of Citizen Petition Regarding Bioequivalence and Exclusivity for Vancocin (vancomycin hydrochloride, USP) Capsules
- Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation
- Amgen to Acquire Privately Held KAI Pharmaceuticals
April 11, 2012
- FDA Drug Safety Communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone
- FAMPYRA, the First Oral Treatment for the Improvement of Walking in MS, is Now Available in Canada
- Jury Rules Against J&J Subsidiary on Antipsychotic
- Takeda to Acquire URL Pharma
- Threshold Pharmaceuticals Earns $20 Million Milestone Payment From Merck Kgaa for Positive Results
- The Results Are In: Nielsen Study Confirms Consumers Take Action After Seeing Ads on Cardinal Health's Retail Pharmacy Digital Advertising Network
- Threshold Earns $20M Milestone Payment
- European Regulators Propose Way Forward for Publication of Full Clinical Trial Data
- Supreme Court to Decide Overtime Fate for Pharmaceutical "Sales Representatives" -- JacksonWhite, Kingsley & Kingsley and Sanford Wittels & Heisler
- Roche sends open letter to Illumina shareholders
April 12, 2012
- Roche issues statement regarding Illumina offer
- Roche on Track for Full-Year Targets ? Good Sales Growth in First Quarter
- Valeant Pharmaceuticals to Acquire Pedinol
- Incoming Teva CEO Reviews Drug Development
- AstraZeneca Launches Dutoprol (metoprolol succinate extended release/hydrochlorothiazide) Tablets for High Blood Pressure in U.S.
- Dainippon Sumitomo Pharma - Change of Executive Officer
- Shire Adds new Technology Platform and Phase 2 Product Candidate to its Regenerative Medicine Business
- PhRMA Member Companies Invested $49.5 Billion in Research and Development in 2011
- AstraZeneca Gets Approval for Blood Pressure Drug
April 13, 2012
- FDA Adds New Side Effects to Finasteride Label
- Mylan Launches First Generic Version of Lescol Capsules
- AVI Biopharma Chief Science Officer Is Leaving
- Affymax and Takeda Announce Centers for Medicare and Medicaid Services Has Assigned a Q-Code for Omontys (Peginesatide) Injection
- BOTOX Cosmetic (onabotulinumtoxinA) Celebrates 10-Year Anniversary of U.S. Food and Drug Administration Approval
- Arkansas Not Counting on $1.2B From Drug Trial Yet
April 16, 2012
- Conformetrix and AstraZeneca Sign Collaborative Agreement - First Collaborative Deal for Conformetrix
- State Law Revised to Attract Research
- Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide (EC145)
- Vanda Pharmaceuticals Acquires Rights to NK-1 Receptor Antagonist from Eli Lilly and Company
- Addex Takes Steps to Rightsize Operations and Position the Company for Future Success
- Piramal Healthcare Limited Acquires Molecular Imaging Development Portfolio of Bayer Pharma
- India's Piramal Acquires Bayer Imaging Portfolio
- FDA Sends Ferring Letter Over Firmagon Sales Aid
- Genzyme and Veracyte Announce Expanded U.S. Availability of the Afirma Thyroid FNA Analysis for Improved Thyroid Nodule Diagnosis
- WaferGen Bio-systems Announces Open Format qPCR Platform and Strategic Realignment
April 17, 2012
- Eisai to Launch Insomnia Treatment Lunesta in Japan
- Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2012 Earnings Per Share of $0.72 Including $0.06 Per Share of Acquisition Amortization
- Johnson & Johnson Reports 2012 First-Quarter Results
- Decision Resources Group Acquires Pinsonault
- Takeda and Metabolon Initiate Research Collaboration to Discover Novel Targets and Biomarkers
April 18, 2012
- Hospira Announces a Nationwide Voluntary Recall of One Lot of Morphine Sulfate Injection, USP 4 MG/ML, (C-II) 1 ML Fill in 2.5 ML Carpuject
- J&J Still Struggling with Recall Effects
- Abbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in First Quarter; Raises Full-Year 2012 Outlook
- Roche decides not to extend its tender offer for Illumina, Inc.
- Consumer Activity on Social Media Sites Dwarfs that of Healthcare Companies, Finds New PwC Study on Social Media in Healthcare
- Illumina Announces Preliminary Voting Results for 2012 Annual Meeting of Stockholders
- Teva Unit Cephalon Wins Appeal on Generic Amrix
- Valeant Pushes Into Latin America With $71M Deal
- Favorable Ruling by United States Supreme Court on Prandin Litigation
- Merck Wins Another FOSAMAX (alendronate sodium) State Court Trial
April 19, 2012
- Human Genome Sciences Announces Unsolicited Offer from GlaxoSmithKline; HGS Board of Directors Authorizes Exploration of Strategic Alternatives
- Merck Serono Opens Israeli Drug Development Incubator
- Baxter Exceeds Revenue and EPS Guidance with Solid First Quarter Financial Results
- Did Merck ......?
- Janssen Creates new Division to Launch TMC435 and Help Conquer Hepatitis C in EMEA
- Human Genome Sciences Announces Unsolicited Offer from GlaxoSmithKline; HGS Board of Directos Authorizes Exploration of Strategic Alternatives
- Cell Therapeutics Enters into Agreement to Acquire Pacritinib, a Novel Highly Selective JAK2 Inhibitor Phase 3 Candidate for Myelofibrosis
- GlaxoSmithKline Sees $2.6bn Bid for US Partner Human Genome Rejected
- New Manhattan Research Report Benchmarks Digital Health Adoption for Key Patient Audiences
- GSK Confirms Offer to Acquire Human Genome Sciences for US$13.00 Per Share in Cash
- Novartis Halts Hepatitis Drug Trial After Death
April 20, 2012
- Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones
- European Medicines Agency Gives New Advice to Better Manage Risk of Adverse Effects on the Heart With Gilenya
- U.S. Pharmaceutical Company Merck Sharp & Dohme Sentenced in Connection with Unlawful Promotion of Vioxx
- Novartis Updates US Label on Gilenya Following Discussions With the FDA
- Novartis Announces Aliskiren Will Continue to Be Available to Appropriate Patients, As FDA Interim Assessment Is Concluded; Product Information Updated
- Statement From Novo Nordisk Regarding the Petition to the FDA By Public Citizen
- Gilead, Bristol Jump on Hepatitis C Drug Study
April 23, 2012
- Report: FDA Strengthens Monitoring of Post-Approval Drug Safety
- Nabi Biopharmaceuticals Announces Definitive Merger Agreement With Biota Holdings Limited
- AstraZeneca Buys Gout Drug Maker Ardea
- AstraZeneca to Acquire Ardea Biosciences for $1.26 Billion Including Lead Product Lesinurad in Phase III Development for Gout
- Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
- Quintiles Names Tom Pike CEO
- Abbott and St. Jude Medical Broaden Alliance for Cardiovascular Products in the United States
April 24, 2012
- Merck Announces Merck Serono Implementation Plans for Its Efficiency Program in Switzerland
- Boehringer Ingelheim on growth path - Successful 2011 financial year
- Pharmaceuticals and Alcon Performed Strongly in the First Quarter; Overall Group Results Impacted By Expected Challenges
- Keryx Rises As Zerenex Succeeds in Japan Study
- Amylin Pharma Rises on Report of New Sale Talks
- Achillion Pharma Slumps on Hepatitis C Drug Data
- FDA Strengthens International Collaboration to Ensure Quality, Safety of Imported Products
- Cetero Reaches Final Resolution with the Food and Drug Administration
- Amgen's First CEO Dies
April 25, 2012
- Flu Vaccination Reminder Via Text Messaging Appears to Improve Rate of Vaccination Among Low-Income Children and Adolescents
- Lilly Reports Solid Start to the Year With First-Quarter 2012 Results, Raises EPS Guidance
- Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
- Amgen's First Quarter 2012 Revenue Increased 9 Percent To $4.0 Billion And Adjusted Earnings Per Share (EPS) Increased 20 Percent To $1.61
- AAIPharma Opens New Lab Facility
- FDA Clears Codexis' New Enzyme-Making Process
- Novartis Could Face A Backlash By Suing the NHS Over Cheap Drugs
- GSK Reports Sales Growth (+2% CER), Further R&D Delivery, Operational Leverage and Continued Returns to Shareholders
- Targacept Announces Reduction in Force and Plan to Focus Resources on Later-Stage Pipeline
- Targacept Announces Reduction in Force and Plan to Focus Resources on Later-Stage Pipeline
- AstraZeneca and The Medicines Company Announce Global Collaboration in Acute Ischemic Heart Disease
- Med Ad News Honors Healthcare Communication Agencies at 23rd Annual Manny Awards
- Icahn Issues Statement Regarding Amylin Pharmaceuticals
- Boston Scientific Announces Canadian Approval and Launch of PROMUS Element Plus Stent System
April 26, 2012
- Watson to Acquire Actavis Group for EUR 4.25 Billion
- Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
- David Brennan to retire as AstraZeneca?s Chief Executive Officer
- Bristol-Myers Squibb Delivers a Solid First Quarter with Strong Operating Results and Key R&D Milestones
- Encouraging Start to the Year for Bayer
- Bristol-Myers Squibb Delivers a Solid First Quarter with Strong Operating Results and Key R&D Milestones
- Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva
- UCB Interim Report ? First Three Months 2012
- BioNJ Announces Keynote Speakers for International BioPartnering Conference on May 10-11, 2012
- The Angiogenesis Foundation Opens Registration for its 10th Annual M. Judah Folkman International Antiangiogenesis Conference
- LES (USA & Canada) to Host Industry Leaders, May 15-17 in Boston, to Examine the Innovation Gap and Other Challenges Facing the Embattled Life Science Industry
April 27, 2012
- New Johnson & Johnson CEO Alex Gorsky Pledges to Make Customers First Priority
- Merck Announces First-Quarter 2012 Financial Results
- Jazz Pharma to Buy EUSA for Up to $700M
- Glaxo Attacks NICE for Rejecting New Lupus Treatment
- Mylan Profit Jumps 23 Percent in First Quarter
- Pfizer Shareholders OK Advisory Compensation Vote
- Sanofi: Strong performance in Q1 2012 including Genzyme contribution
- Novo Nordisk A/S: Operating profit increased by 18% in the first quarter of 2012 (27 April 2012)
- Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences
- Peregrine's Novel PS-Targeting Technology Platform to Be Highlighted at The New York Academy of Sciences Symposium on May 1, 2012
- Transition Therapeutics Announces ELND-005 Presentations at the American Academy of Neurology Meeting
- EVENT ANNOUNCEMENT: BioFlorida's 9th Celebration of Biotechnology
- Merck Wins U.S. ZETIA (ezetimibe)/ VYTORIN (ezetimibe/simvastatin) Patent Infringement Lawsuit
April 30, 2012
- Watson First Quarter 2012 Non-GAAP EPS Increases 84% to $1.64; Net Revenue Increases 74% to $1.5 Billion
- Teva Reaches Compromise on Epinephrine Injector
- Shire's Stumble Could Help Protalix on Gaucher's Treatment
- Mylan Announces Settlement Agreement for its First-to-File Generic Version of Nuvigil
- Mylan Announces Settlement Agreement for its First-to-File Generic Version of Nuvigil
- Cannabis Science Makes Medical Moves at The 7th Patients Out of Time medical cannabis conference in Tucson at the Loews Ventana Canyon Resort
- Heart Rhythm Society Kicks Off ?Cardiac Arrhythmia Awareness Month? in Massachusetts
- Alexion to Present at Deutsche Bank Securities 37th Annual Health Care Conference
- Accelrys Announces May 2012 North American User Group Meeting Co-Located With IMACS
- Amylin Pharmaceuticals to Present at Deutsche Bank 37th Annual Health Care Conference
- Monthly News Round Up - April 2012
